Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial - Diabetologia Aims/hypothesis Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become an important option in clinical use for type 2 diabetes due to their dual benefits of glycaemic management and metaboli...

Efsubaglutide alfa, a long-acting GLP 1RA, significantly lowers HbA1c and weight in drug-naive #T2D. The seamless Phase IIb/III SUPER1 trial confirms efficacy and safety. #GLP1RA #Innogen link.springer.com/article/10.1...

Obesity Weekly News – July 8th 2025 China’s Dual GCG/GLP-1 Breakthrough, Innogen’s 2026 Goal, Zepbound’s Korea Launch & More In this week’s Obesity Updates, we spotlight the […] The post Obesity Weekly News – July 8th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Obesity Weekly News – July 8th 2025 #News #mazdutide #innogen #clinicaltrials Comment below!

Obesity Weekly News – July 8th 2025 China’s Dual GCG/GLP-1 Breakthrough, Innogen’s 2026 Goal, Zepbound’s Korea Launch & More In this week’s Obesity Updates, we spotlight the […] The post Obesity Weekly News – July 8th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Obesity Weekly News – July 8th 2025 #News #mazdutide #innogen #clinicaltrials Comment below!

Obesity Weekly News – July 8th 2025 China’s Dual GCG/GLP-1 Breakthrough, Innogen’s 2026 Goal, Zepbound’s Korea Launch & More In this week’s Obesity Updates, we spotlight the […] The post Obesity Weekly News – July 8th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Obesity Weekly News – July 8th 2025 #News #mazdutide #innogen #clinicaltrials Comment below!

He is at Milford-Haven. Read, and tell me
How far ’tis thither.
… How far it is
To this same blessed Milford. And by th’ way
Tell me how Wales was made so happy as
T’ inherit such a haven.
Shakespeare, CYMBELINE, 3.2
#BookWormSat #MilfordHaven #Wales #Cymru #Cymbeline #Cynfelyn #Innogen #Imogen